Patents Assigned to BONAC CORPORATION
  • Publication number: 20230357767
    Abstract: The present invention aims to provide a new nucleic acid molecule for suppressing expression of the target gene, which (1) has a gene expression suppressing activity equivalent to or higher than that of siRNA, (2) shows no off-target effect of the sense strand, and (3) makes it possible to design a wider range of antisense strand sequences (extends the range of targetable sequences). Since the nucleic acid molecule of the following formula: wherein each symbol is as defined in the DESCRIPTION, has the superior properties of the above-mentioned (1) to (3), it is extremely useful as a novel gene expression inhibitor that replaces conventional siRNA.
    Type: Application
    Filed: August 25, 2021
    Publication date: November 9, 2023
    Applicant: BONAC CORPORATION
    Inventors: Atsushi SHIBATA, Tadaaki OHGI, Tomoaki ABE, Chisato EMURA, Eriko AOKI, Hisao SHIROHZU, Yusuke IWAKAMI, Melisa ACOSTA RAMIREZ, Kota NAITO
  • Publication number: 20230183283
    Abstract: The present invention aims to provide a method of producing, more efficiently at a high purity, a phosphoramidite preferable for the production (synthesis) of a nucleic acid. Using a coupling reaction of an ether represented by the following chemical formula (105), an enantiomer, tautomer or stereoisomer thereof, or a salt thereof, and a glycoside compound, phosphoramidite that enables efficient synthesis of nucleic acid can be obtained: wherein n is a positive integer, and R and R? are the same or different and each is a hydrogen atom or a hydroxyl-protecting group.
    Type: Application
    Filed: October 13, 2017
    Publication date: June 15, 2023
    Applicant: BONAC CORPORATION
    Inventors: Tadaaki OHGI, Eriko AOKI, Takashi KINOSHITA, Akihiro ITOH, Chisato EMURA
  • Patent number: 11518994
    Abstract: The invention provides an artificial sgRNA and a CRISPR/Cas9 system by combining the artificial sgRNA and Cas9. Activity of the sgRNA can be retained even when a nucleotide linker region for forming a single strand by linking the 3?-terminal of crRNA and the 5?-terminal of tracrRNA in sgRNA is substituted with an amino acid derivative linker, when the linker region existing between stem-loop 1 and stem-loop 2 of tracrRNA and/or the loop portion of stem-loop 2 are/is substituted with an amino acid derivative linker, or when an amino acid derivative linker is added/inserted into the vicinity of the 5?-terminal and/or the 3?-terminal of sgRNA. Stability in vivo can be improved by introducing one or more amino acid derivative linkers into the sgRNA.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: December 6, 2022
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Tadaaki Ohgi, Takashi Kinoshita
  • Patent number: 11142769
    Abstract: The present invention provides a single-stranded nucleic acid molecule having a delivery function and capable of inhibiting expression of a target gene. The single-stranded nucleic acid molecule of the present invention is a single-stranded nucleic acid molecule composed of a region (Xc), a linker region (Lx) and a region (X), wherein said region (Xc) is complementary to said region (X), at least one of said region (X) and said region (Xc) contains an expression inhibitory sequence that inhibits expression of the target gene, and a bio-related substance having a delivery function is bonded to at least one selected from the group consisting of the 5?-terminus, the 3?-terminus, and said linker region (Lx).
    Type: Grant
    Filed: March 26, 2016
    Date of Patent: October 12, 2021
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Shiori Kato, Tadaaki Ohgi
  • Publication number: 20210188895
    Abstract: The invention provides a single-stranded nucleic acid molecule and a production method thereof. The single-stranded nucleic acid molecule is represented by formula (I): wherein each symbol is as described in the description.
    Type: Application
    Filed: October 12, 2018
    Publication date: June 24, 2021
    Applicant: BONAC CORPORATION
    Inventors: Tadaaki OHGI, Chisato EMURA, Takashi KINOSHITA
  • Patent number: 11027023
    Abstract: The present invention provides a natural type miRNA, which is a single-stranded nucleic acid containing X region and Y region, wherein the 3?-terminus of said X region and the 5?-terminus of said Y region are linked via a linker region of a non-nucleotide structure, the X region contains (a) a guide strand sequence or (b) a passenger strand sequence of a mature miRNA, when the X region contains (a), the Y region contains a passenger strand sequence of the mature miRNA, when the X region contains (b), the Y region contains a guide strand sequence of the mature miRNA, and the guide strand sequence and the passenger strand sequence form a double-stranded structure.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: June 8, 2021
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Yasuhiko Yoshida, Shiori Kato, Tadaaki Ohgi
  • Patent number: 10934542
    Abstract: The invention provides an artificial match-type miRNA utilizing miRNA. In particular, the invention provides a single strand nucleic acid containing an X region and a Y region, wherein the 3?-terminal of the X region and the 5?-terminal of the Y region are linked via a linker region of a non-nucleotide structure, the X region contains a guide strand sequence of a mature miRNA, and the Y region contains a sequence completely complementary to the X region is an artificial match-type miRNA. The artificial match-type miRNA can suppress expression of the target gene.
    Type: Grant
    Filed: December 27, 2014
    Date of Patent: March 2, 2021
    Assignees: BONAC CORPORATION, TOKYO MEDICAL UNIVERSITY
    Inventors: Masahiko Kuroda, Shinichiro Ohno, Eriko Aoki, Yasuhiko Yoshida, Shiori Kato, Tadaaki Ohgi
  • Patent number: 10751426
    Abstract: The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5?-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3? (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 25, 2020
    Assignees: BONAC CORPORATION
    Inventors: Taimu Yamada, Hidekazu Toyofuku, Kohei Tahara, Risako Onodera, Hirofumi Takeuchi
  • Publication number: 20200038427
    Abstract: The present invention aims to provide a nucleic acid molecule having improved stability in serum and capable of exhibiting a gene expression regulation function after transfer into the cell. A cyclic nucleic acid molecule represented by the following formula (A): wherein each symbol is as described in the DESCRIPTION can be synthesized easily at a low cost, and can inhibit the translation of a protein encoded by the gene. Since the cyclic nucleic acid molecule of the present invention can inhibit the expression of a target gene as described above, for example, it is useful as a pharmaceutical product, a diagnostic agent, an agricultural chemical, and a tool for conducting research on agriculture, medical science, life science, and the like.
    Type: Application
    Filed: March 30, 2018
    Publication date: February 6, 2020
    Applicant: BONAC CORPORATION
    Inventors: Tadaaki OHGI, Chisato EMURA, Junichi YASUOKA, Yutaka EGUCHI
  • Publication number: 20190382758
    Abstract: The invention provides an artificial sgRNA and a CRISPR/Cas9 system by combining the artificial sgRNA and Cas9. Activity of the sgRNA can be retained even when a nucleotide linker region for forming a single strand by linking the 3?-terminal of crRNA and the 5?-terminal of tracrRNA in sgRNA is substituted with an amino acid derivative linker, when the linker region existing between stem-loop 1 and stem-loop 2 of tracrRNA and/or the loop portion of stem-loop 2 are/is substituted with an amino acid derivative linker, or when an amino acid derivative linker is added/inserted into the vicinity of the 5?-terminal and/or the 3?-terminal of sgRNA. Stability in vivo can be improved by introducing one or more amino acid derivative linkers into the sgRNA.
    Type: Application
    Filed: January 30, 2017
    Publication date: December 19, 2019
    Applicant: BONAC CORPORATION
    Inventors: Eriko AOKI, Tadaaki OHGI, Takashi KINOSHITA
  • Patent number: 10377788
    Abstract: The invention provides a production method of a glycoside compound or a salt thereof, which includes subjecting a thioether compound and an alcohol compound to a coupling reaction in the presence of a halogenating agent, a desiccant and a Lewis acid, and then distillation in the presence of at least one kind of additive selected from a sulfur-containing antioxidant and a maleimide group-containing compound to give a thioether compound and a step of subjecting a glycoside compound and a thioether compound to a coupling reaction in the presence of a halogenating agent, a desiccant and a Lewis acid to give a glycoside compound. By this method, a phosphoramidite preferable for the production (synthesis) of a nucleic acid can be produced more efficiently at a high purity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 13, 2019
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Takashi Kinoshita, Akihiro Itoh, Tadaaki Ohgi
  • Patent number: 10337009
    Abstract: The invention provides a single-stranded nucleic acid molecule of (A) or (B) containing a TGF-?1 gene expression inhibitory sequence. The single-stranded nucleic acid molecule (A) consists of region (Xc), linker region (Lx) and region (X) from the 5?-side to the 3?-side, wherein linker region (Lx) has a non-nucleotide structure containing at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of region (X) and region (Xc) contains the expression inhibitory sequence.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: July 2, 2019
    Assignee: BONAC CORPORATION
    Inventors: Takahiro Matsumoto, Hidekazu Toyofuku
  • Patent number: 10238752
    Abstract: The invention provides a single-stranded nucleic acid capable of inhibiting expression of a target gene having a delivery function. The nucleic acid contains, from the 5?-side to the 3?-side, a 5?-side region (Xc), a linker region (Lx), an inner region (Z), a linker region (Ly) and a 3?-side region (Yc) in this order, wherein the inner region (Z) is constituted by linkage of the inner 5?-side region (X) and the inner 3?-side region (Y), the 5?-side region (Xc) is complementary to the inner 5?-side region (X), the 3?-side region (Yc) is complementary to the inner 3?-side region (Y), at least one of the inner region (Z), the 5?-side region (Xc) and the 3?-side region (Yc) comprises an expression inhibitory sequence that inhibits expression of a target gene, and at least one of the 5?-terminus, the 3?-terminus, the linker region (Lx) and the linker region (Ly) is bound to a bio-related substance.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: March 26, 2019
    Assignee: Bonac Corporation
    Inventors: Tadaaki Ohgi, Eriko Aoki, Chisato Emura, Tomohiro Hamasaki
  • Patent number: 10233446
    Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 19, 2019
    Assignee: Bonac Corporation
    Inventors: Tadaaki Ohgi, Hisao Shirohzu, Hiroshi Suzuki, Tomohiro Hamasaki, Takayuki Mizutani
  • Publication number: 20190010503
    Abstract: The present invention provides a single-stranded nucleic acid molecule inhibiting expression of a prorenin gene or a prorenin receptor gene, comprising only region (X), linker region (Lx) and region (Xc), wherein the aforementioned linker region (Lx) has a non-nucleotide structure comprising at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of the aforementioned region (X) and the aforementioned region (Xc) comprises an expression inhibitory sequence comprising a nucleotide sequence consisting of at least 18 continuous nucleotides in any of an expression inhibitory sequence of a prorenin gene shown in SEQ ID NO: 1 to 5 and an expression inhibitory sequence of prorenin receptor gene shown in SEQ ID NO: 6 to 11.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 10, 2019
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, TOKYO MEDICAL UNIVERSITY, BONAC CORPORATION
    Inventors: Susumu ISHIDA, Atsuhiro KANDA, Masahiko KURODA, Hidekazu TOYOFUKU
  • Publication number: 20180339064
    Abstract: The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5?-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3? (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 29, 2018
    Applicants: BONAC CORPORATION
    Inventors: Taimu YAMADA, Hidekazu TOYOFUKU, Kohei TAHARA, Risako ONODERA, Hirofumi TAKEUCHI
  • Publication number: 20180326091
    Abstract: The present invention provides a natural type miRNA, which is a single-stranded nucleic acid containing X region and Y region, wherein the 3?-terminus of said X region and the 5?-terminus of said Y region are linked via a linker region of a non-nucleotide structure, the X region contains (a) a guide strand sequence or (b) a passenger strand sequence of a mature miRNA, when the X region contains (a), the Y region contains a passenger strand sequence of the mature miRNA, when the X region contains (b), the Y region contains a guide strand sequence of the mature miRNA, and the guide strand sequence and the passenger strand sequence form a double-stranded structure.
    Type: Application
    Filed: December 25, 2015
    Publication date: November 15, 2018
    Applicant: BONAC CORPORATION
    Inventors: Eriko AOKI, Yasuhiko YOSHIDA, Shiori KATO, Tadaaki OHGI
  • Patent number: 9988415
    Abstract: The invention provides a glucoside compound, which is capable of providing a phosphoramidite, which can be produced at low cost and can produce a nucleic acid in high yield and with high purity. The glycoside compound has the formula wherein B, R1, R2, and R3 are as described herein.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: June 5, 2018
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Hiroshi Suzuki, Akihiro Itoh
  • Publication number: 20180119151
    Abstract: The present invention provides a single-stranded nucleic acid molecule having a delivery function and capable of inhibiting expression of a target gene. The single-stranded nucleic acid molecule of the present invention is a single-stranded nucleic acid molecule composed of a region (Xc), a linker region (Lx) and a region (X), wherein said region (Xc) is complementary to said region (X), at least one of said region (X) and said region (Xc) contains an expression inhibitory sequence that inhibits expression of the target gene, and a bio-related substance having a delivery function is bonded to at least one selected from the group consisting of the 5?-terminus, the 3?-terminus, and said linker region (Lx).
    Type: Application
    Filed: March 26, 2016
    Publication date: May 3, 2018
    Applicant: BONAC CORPORATION
    Inventors: Eriko AOKI, Shiori KATO, Tadaaki OHGI
  • Publication number: 20180099004
    Abstract: The present invention provides a single stranded nucleic acid molecule represented by the following formula (I): (I) (SEQ?ID?NO:?1) 5?-uagcaccauuugaaaucaguguucc-P- ggaacacugauuucaaauggugcuauu-3? wherein —P— shows a proline derivative linker represented by the following formula (Ia): an agent for treating corneal diseases such as ocular surface disorders and the like, comprising the single stranded nucleic acid molecule as an active ingredient.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: THE UNIVERSITY OF TOKYO, TOKYO MEDICAL UNIVERSITY, BONAC CORPORATION
    Inventors: Hirofumi TAKEUCHI, Tomohiko USUI, Masahiko KURODA, Masakatsu TAKANASHI, Shinichiro OHNO, Hidekazu TOYOFUKU, Kohei TAHARA, Risako ONODERA